NCT06621277 JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors
| NCT ID | NCT06621277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Heidelberg |
| Condition | Gastrointestinal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2023-10-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2023-10-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
JUMP\_START aims to assess the needs of individuals aged ≤ 50 years with gastrointestinal (GI) tumors and implement a tailored support and counseling program at the University Hospital Heidelberg and the National Center for Tumor Diseases (NCT). In phase 1A, 12-15 individuals aged ≤ 50 years with GI tumors will be interviewed via telephone using semi-structured interviews to obstain a detailed understanding of the life situation, the burdens, and the care situation within the structures of the NCT Heidelberg. In phase 1B, the care networks of young patients with GI tumors beyond the NCT, including the analysis of changes and important access routes/possible gatekeepers, will be explored using so-called ego-centered network analyses, in comparison with patients who received a GI tumor diagnosis after the age of 50. In response to the results of phase 1A and 1B, the care services for young patients with GI tumors will be optimized, and tailored counseling programs will be developed in phase 2. These project phases will be accompanied by Quality of Life assessments using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires. All patients with GI tumors (regardless of potential inclusion in phase 1A or 1B) will receive the EORTC questionnaires once. In phase 2, Quality of Life will be assessed every 6 months.
Eligibility Criteria
Inclusion Criteria: * Individuals aged ≥ 18 and ≤ 50 years receiving treatment for a GI tumor at the Heidelberg University Hospital * Sufficient knowledge of the German language * Capable of providing informed consent * Additional recruitment for Phase 1B and Quality of Life assessments: Patients with GI tumor aged ≥ 51 years Exclusion Criteria: * Individuals with a GI tumor diagnosis after the age of 50 (except in Phase 1B and for Quality of Life assessments) * Individuals with a GI tumor diagnosis under the age of 18 * Lack of capacity to consent and/or absence of informed consent * Insufficient knowledge of the German language * Severe cognitive impairments
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06621277 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastrointestinal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06621277 currently recruiting?
Yes, NCT06621277 is actively recruiting participants. Contact the research team at jump-start.nct@med.uni-heidelberg.de for enrollment information.
Where is the NCT06621277 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT06621277 clinical trial?
NCT06621277 is sponsored by University Hospital Heidelberg. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.